A partial rotator cuff tear is usually managed non-operatively first, and the literature supports starting there: a narrative review of non-operative management reports that most studies show an overall success rate of around 75% across the tear types and populations reviewed.1 That figure is an aggregate, not a forecast for your shoulder. What it justifies is a structured conservative plan before anything else is considered.
Key takeaways
- A partial tear means the tendon is damaged without being fully detached from the bone.
- Across the mixed tear types and populations in one narrative review, most studies reported roughly 75% success with non-operative treatment.1
- Rehabilitation is the core of that plan, alongside load management and activity modification.
- Orthobiologics are considered when an organized conservative plan has been completed and symptoms remain limiting — not as a substitute for it.
- Trial evidence for injecting biologics into partial-thickness tears exists but is small: one randomized trial compared 11 patients receiving adipose-derived regenerative cells against 5 receiving corticosteroid.2
What a partial tear is, and why non-surgical care comes first
In a partial-thickness tear the tendon is damaged in a way that does not completely detach it from the bone. Pain often comes from more than one source at once — the tendon itself, the bursa, and the altered movement pattern the shoulder adopts to work around the injury.
Because several structures are contributing, a plan aimed only at the tendon frequently underperforms. The evaluation is built to find out which of those contributors is doing the most work in your case.
What the evaluation covers
- Range of motion limits and the movements that reliably provoke symptoms
- Strength testing and scapular mechanics
- Imaging findings and what they do and do not predict
- What has already been tried, for how long, and whether it was completed
What non-operative management involves
Physical therapy is the centerpiece, but a plan that is only a list of exercises tends not to hold. Load management, sleep positioning, and strengthening that addresses the shoulder blade as well as the cuff usually matter as much as work aimed at the tendon alone.
The elements of a plan you can actually follow
- Therapeutic exercise targeting strength and motor control
- Education on load management and symptom-guided progression
- Manual and mobility work where it is indicated
- Image-guided injection in selected cases, positioned within the plan rather than replacing it
How that sequence is built and monitored is described in our approach to conservative-first planning.
Where orthobiologics enter
Orthobiologics are discussed when an organized conservative plan has been completed and the shoulder remains limiting. The purpose is not to promise a structural repair of the tendon but to address the tissue environment and the symptom drivers that have not responded.
Delivery and targeting
Platelet-rich plasma approaches differ by where and how the material is placed, and for shoulder problems image guidance is used to reach the tissue where symptoms originate. The principle is the same one that governs every biologic decision here: the delivery has to match the target, rather than one approach being applied to every problem. The categories are described under orthobiologic services.
What the trial evidence covers
One randomized trial studied symptomatic partial-thickness tears in patients who had not responded to at least six weeks of physical therapy, comparing a single injection of fresh, uncultured, autologous adipose-derived regenerative cells against a single corticosteroid injection.2 Patients were assessed at roughly 33 and 41 months after treatment, and the authors reported the cell injection as safe and more effective than corticosteroid.
The trial enrolled 11 patients in the cell arm and 5 in the corticosteroid arm.2 At that size, the result is a signal worth knowing about and not a basis for telling you what will happen.
The wider biological picture
Local injection is rarely the whole story. Systemic inflammation and metabolic factors influence how tissue responds, which is why those are assessed in the same evaluation rather than treated as a separate specialty. That includes topics covered under physician-directed peptide and longevity medicine, which are discussed as clinical subjects and are not sold.
When conservative care has been exhausted
Regen.MD is conservative-first by design, and Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon. When conservative measures have genuinely been exhausted and the shoulder is still limiting, surgery is available and is discussed directly. The sequence matters: surgery follows completed conservative care rather than replacing the attempt at it.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently asked questions
What does the 75% non-operative success figure actually mean for me?
Less than it sounds, and it is worth being clear about why. It is an aggregate across a body of literature covering mixed tear types, tear sizes, and age groups, not a rate measured in patients with your specific tear.1
It supports starting non-operatively as a reasonable default. It does not forecast your individual result. The conditions we work through this way are listed on our conditions page.
Is there trial evidence for injecting biologics into a partial-thickness tear?
There is, and it is small. One randomized trial assigned patients who had not responded to at least six weeks of physical therapy to a single injection of autologous adipose-derived regenerative cells or a single corticosteroid injection, following them past three years.2
The trial reported the cell injection as safe and more effective than corticosteroid, with 11 patients in one arm and 5 in the other. That is a real result at a size that cannot settle the question. The wider evidence base is collected in the Regen.MD library.
When do you stop conservative care and move on?
When an organized plan has been genuinely followed and the shoulder is still limiting what you need it to do. The threshold is a plan actually completed rather than a period of time elapsed, because an incomplete rehabilitation course tells you nothing about whether rehabilitation would have worked.
What comes after that point is described on our shoulder surgery alternatives page.
Who evaluates the shoulder and decides the plan?
The Clinical Evaluation is paid and physician-led. Dr. Gurpreet Singh Padda, MD, MBA, MHP reviews the history, examination, and imaging, and is a surgeon, which means the conversation about whether and when to operate happens with someone who performs surgery rather than being referred away.
His background and scope of practice are on the Dr. Padda page.
Sources
- Petri M, et al. “Non-Operative Management of Rotator Cuff Tears.” The Open Orthopaedics Journal, 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5041208/
- Lundeen M, Hurd JL, Hayes M, et al. “Management of partial-thickness rotator cuff tears with autologous adipose-derived regenerative cells is safe and more effective than injection of corticosteroid.” Scientific Reports, 2023;13:19348. https://www.nature.com/articles/s41598-023-46653-4